Join
Live feed
·
PRReleasevia Quantisnow
Hoth Therapeutics Inc. logo

Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model

ByQuantisnow·Wall Street's wire, on your screen.
HOTH· Hoth Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track HOTH (Hoth Therapeutics Inc.) and more on Quantisnow.